Absence of Exposed Bone Following Dental Extraction in Beagle Dogs Treated with 9 Months of High-dose Zoledronic Acid Combined with Dexamethasone

Overview

Journal J Oral Maxillofac Surg

Specialties Dentistry
General Surgery

Date 2013 Feb 5

PMID 23375897

Citations 17

Authors

Matthew R Allen

Tien-Min Gabriel Chu

Salvatore L Ruggiero

Affiliations

Soon will be listed here.

Abstract

Purpose: Factors contributing to osteonecrosis of the jaw with anti-remodeling drug treatment are unclear. Epidemiologic and experimental studies have suggested the combination of bisphosphonates and dexamethasone results in osteonecrosis of the jaw more often than either agent alone. The goal of this study was to assess the combination of these 2 drugs in a large animal model previously shown to be susceptible to exposed bone in the oral cavity when treated with bisphosphonates.

Materials And Methods: Skeletally mature beagle dogs were untreated controls or treated with zoledronic acid (ZOL), dexamethasone (DEX), or ZOL plus DEX. ZOL and DEX were given at doses based on those used in humans. All animals underwent single molar extraction at 7 and 8 months after the start of the study. Extraction sites were obtained at month 9 for assessment of osseous healing using micro-computed tomography and histology.

Results: No animals were observed to have exposed bone after dental extraction, yet 1 animal treated with ZOL and 1 treated with ZOL plus DEX had severely disrupted extraction sites as viewed by computed tomography and histology. These 2 animals had an intense periosteal reaction that was less obvious but still present in all ZOL-treated animals and absent from untreated animals. There was no significant difference in bone volume within the socket among groups at 4 or 8 weeks after healing, yet the ratio of surface to volume was significantly higher in animals treated with ZOL plus DEX at 8 weeks compared with control animals.

Conclusions: These findings suggest a more complex pathophysiology to osteonecrosis of the jaw than is implied by previous epidemiologic studies and those in rodents and raise questions about the potential role of DEX in its etiology.

Citing Articles

Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL‑mediated NF‑κB and JNK and their downstream signalling pathways.

Huang X, Liu C, Shi X, Cheng Y, Zhou Q, Li J Mol Med Rep. 2021; 25(2).

PMID: 34935053 PMC: 8711024. DOI: 10.3892/mmr.2021.12575.

Preclinical models of medication-related osteonecrosis of the jaw (MRONJ).

Aguirre J, Castillo E, Kimmel D Bone. 2021; 153:116184.

PMID: 34520898 PMC: 8743993. DOI: 10.1016/j.bone.2021.116184.

Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.

Kawahara M, Kuroshima S, Sawase T Int J Implant Dent. 2021; 7(1):47.

PMID: 33987769 PMC: 8119587. DOI: 10.1186/s40729-021-00323-0.

Pyk2 deficiency enhances bone mass during midpalatal suture expansion.

Sun J, Eleniste P, Utreja A, Turkkahraman H, Liu S, Bruzzaniti A Orthod Craniofac Res. 2020; 23(4):501-508.

PMID: 32562339 PMC: 10205047. DOI: 10.1111/ocr.12402.

Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors.

Wan J, Sheeley D, Somerman M, Lee J Bone Res. 2020; 8:14.

PMID: 32195012 PMC: 7064532. DOI: 10.1038/s41413-020-0088-1.

References

Cardaropoli G, Araujo M, Lindhe J . Dynamics of bone tissue formation in tooth extraction sites. An experimental study in dogs. J Clin Periodontol. 2003; 30(9):809-18. DOI: 10.1034/j.1600-051x.2003.00366.x. View

Allen M, Pandya B, Ruggiero S . Lack of correlation between duration of osteonecrosis of the jaw and sequestra tissue morphology: what it tells us about the condition and what it means for future studies. J Oral Maxillofac Surg. 2010; 68(11):2730-4. PMC: 2963684. DOI: 10.1016/j.joms.2010.05.090. View

Parfitt A, Drezner M, Glorieux F, Kanis J, MALLUCHE H, Meunier P . Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2(6):595-610. DOI: 10.1002/jbmr.5650020617. View

Lacy M, Dispenzieri A, Gertz M, Greipp P, Gollbach K, Hayman S . Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006; 81(8):1047-53. DOI: 10.4065/81.8.1047. View

Huja S, Mason A, Fenell C, Mo X, Hueni S, DAtri A . Effects of short-term zoledronic acid treatment on bone remodeling and healing at surgical sites in the maxilla and mandible of aged dogs. J Oral Maxillofac Surg. 2010; 69(2):418-27. DOI: 10.1016/j.joms.2010.05.062. View

Sonis S, Watkins B, Lyng G, Lerman M, Anderson K . Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol. 2008; 45(2):164-72. DOI: 10.1016/j.oraloncology.2008.04.013. View

Allen M, Kubek D, Burr D . Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res. 2009; 25(1):98-105. PMC: 3153321. DOI: 10.1359/jbmr.090713. View

Mavrokokki T, Cheng A, Stein B, Goss A . Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007; 65(3):415-23. DOI: 10.1016/j.joms.2006.10.061. View

Hayman A, Jones S, Boyde A, Foster D, Colledge W, Carlton M . Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. Development. 1996; 122(10):3151-62. DOI: 10.1242/dev.122.10.3151. View

10.

Hoff A, Toth B, Altundag K, Johnson M, Warneke C, Hu M . Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008; 23(6):826-36. PMC: 2677083. DOI: 10.1359/jbmr.080205. View

11.

Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S . Osteonecrosis of the jaw: more research needed. J Bone Miner Res. 2006; 21(10):1503-5. DOI: 10.1359/jbmr.060712. View

12.

Vigorita V, Silver J, Eisemon E . Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report. Skeletal Radiol. 2012; 41(7):861-5. DOI: 10.1007/s00256-012-1407-4. View

13.

Clemons M, Dranitsaris G, Ooi W, Yogendran G, Sukovic T, Wong B . Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol. 2006; 24(30):4895-900. DOI: 10.1200/JCO.2006.05.9212. View

14.

Allen M, Burr D . Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg. 2008; 66(5):987-94. PMC: 2464292. DOI: 10.1016/j.joms.2008.01.038. View

15.

Weinstein R, Roberson P, Manolagas S . Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009; 360(1):53-62. PMC: 2866022. DOI: 10.1056/NEJMoa0802633. View

16.

Weber D, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer E . Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357(21):2133-42. DOI: 10.1056/NEJMoa070596. View

17.

Pap T, Claus A, Ohtsu S, Hummel K, Schwartz P, Drynda S . Osteoclast-independent bone resorption by fibroblast-like cells. Arthritis Res Ther. 2003; 5(3):R163-73. PMC: 165048. DOI: 10.1186/ar752. View

18.

Aghaloo T, Kang B, Sung E, Shoff M, Ronconi M, Gotcher J . Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J Bone Miner Res. 2011; 26(8):1871-82. PMC: 3596511. DOI: 10.1002/jbmr.379. View

19.

Hollberg K, Hultenby K, Hayman A, Cox T, Andersson G . Osteoclasts from mice deficient in tartrate-resistant acid phosphatase have altered ruffled borders and disturbed intracellular vesicular transport. Exp Cell Res. 2002; 279(2):227-38. DOI: 10.1006/excr.2002.5612. View

20.

Aghaloo T, Felsenfeld A, Tetradis S . Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg. 2010; 68(5):959-63. PMC: 2880179. DOI: 10.1016/j.joms.2009.10.010. View